Abstract Number: 1298 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Parkinson’s Disease in Older Adults: A Study of U.S. Medicare Data
Background/Purpose: In the presence of limited available data, our objective was to assess the association of gout with the risk of incident Parkinson’s disease (PD)…Abstract Number: 1300 • 2018 ACR/ARHP Annual Meeting
The Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Gout Patients: A Population Based Study
Background/Purpose: The metabolic syndrome (MS) is common among gout patients. The metabolic syndrome is diagnosed when a patient has at least 3 of the following…Abstract Number: 1302 • 2018 ACR/ARHP Annual Meeting
Opioid Analgesic Use in Acute Gout Patients Discharged from the Hospital
Background/Purpose: The Health and Human Services has declared the opioid epidemic as a public health emergency. It has been demonstrated that even short exposures to…Abstract Number: 1980 • 2018 ACR/ARHP Annual Meeting
Comprehensive Association Analysis between Rare and Common ABCG2 Variants and Gout Susceptibility
Background/Purpose: We have reported that ABCG2 has an important role in both renal and intestinal urate excretion and these common variants as rs72552713 (Q126X) and…Abstract Number: 2176 • 2018 ACR/ARHP Annual Meeting
The Association of Gout with Incident Giant Cell Arteritis in Older Adults
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis that affects large and medium sized arteries in people 50 years or older. Gout, the most common…Abstract Number: 2205 • 2018 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Measurement of Dissolution of Urate Deposits Associated with Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin By Dual Energy Computed Tomography
Background/Purpose: Pegylated uricases are therapies for treatment of severe chronic gout, particularly for rapid resolution of tophi. However, uricases are limited by induction of anti-drug…Abstract Number: 2217 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Early Onset Gout in Outpatient Setting
Background/Purpose: There has been an increase in the prevalence of gout over the past two decades, with increasing number of patients presenting at younger age.…Abstract Number: 2220 • 2018 ACR/ARHP Annual Meeting
Gout, Flares and Allopurinol Use: A Population Based Study
Background/Purpose: Gout flares may often be self-managed, but there is a paucity of population-based data. The aim of this study was to determine the prevalence…Abstract Number: 2221 • 2018 ACR/ARHP Annual Meeting
Systematic Genetic Analysis of Early-Onset Gout: ABCG2 141K Is the Strongest Predictor
Background/Purpose: Although increasing age is an important risk factor for development of gout, disease can develop in younger people. The aim of this study was…Abstract Number: 2222 • 2018 ACR/ARHP Annual Meeting
Construct Validity of Provisional Remission Criteria for Gout: A Dual Energy CT Study
Background/Purpose: Provisional domains and definitions for gout remission criteria have been proposed using consensus methodology (de Lautour et al, Arthritis Care Res 2016). These criteria…Abstract Number: 2224 • 2018 ACR/ARHP Annual Meeting
Interactions between Serum Urate-Associated Genetic Variants and Sex on Gout Risk in a European Population
Background/Purpose: Sex-specific differences in the effect size of genetic variants on serum urate levels have been described, with SLC2A9 variants having a greater influence on…Abstract Number: 2225 • 2018 ACR/ARHP Annual Meeting
Exploring the Relationship between Gout and Diffuse Idiopathic Skeletal Hyperostosis (DISH): An Epidemiologic and Genetic Study
Background/Purpose: Gout has been reported to be a risk factor for development of diffuse idiopathic skeletal hyperostosis (DISH), a condition characterized by abnormal bone formation…Abstract Number: 2226 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study
Background/Purpose: The pursuit of a link between gout/hyperuricemia and dementia has led to contradictory results. Most observational studies, including population-based studies, showed that hyperuricemia was…Abstract Number: 2227 • 2018 ACR/ARHP Annual Meeting
What Should be the Goals of Gout Therapy? a Patient Perspective
Background/Purpose: In the absence of any available current evidence, our primary objective was to assess the goals of gout treatment from a patient perspective and…Abstract Number: 2228 • 2018 ACR/ARHP Annual Meeting
A Validated Script Concordance Test Demonstrates Interdisciplinary Differences in Clinical Decision-Making When Using Allopurinol to Treat Gout in Chronic Kidney Disease
Background/Purpose: The safety of allopurinol in the setting of chronic kidney disease (CKD) has been a controversial issue for many years. The perceived increased risk…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »